FDA Grants Accelerated Approval to Futibatinib for Locally Advanced, Metastatic Cholangiocarcinoma
October 3rd 2022Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
Read More
Expert: ‘We All Hold Implicit Biases’ That May Contradict Explicit Beliefs, Impact Patient Health
October 2nd 2022As individuals in a society, all people have implicit, or unconscious, beliefs that they have been socialized to hold; however, health care professionals’ implicit biases can impact patients’ lives.
Read More